Merus NV (NASDAQ:MRUS) Expected to Announce Quarterly Sales of $8.43 Million

Wall Street analysts expect that Merus NV (NASDAQ:MRUS) will announce $8.43 million in sales for the current fiscal quarter, according to Zacks Investment Research. Two analysts have provided estimates for Merus’ earnings, with the highest sales estimate coming in at $8.88 million and the lowest estimate coming in at $7.98 million. Merus posted sales of $7.81 million in the same quarter last year, which suggests a positive year over year growth rate of 7.9%. The firm is expected to issue its next earnings report on Thursday, July 25th.

According to Zacks, analysts expect that Merus will report full-year sales of $33.61 million for the current fiscal year, with estimates ranging from $32.54 million to $34.68 million. For the next fiscal year, analysts expect that the business will post sales of $56.60 million, with estimates ranging from $31.92 million to $81.28 million. Zacks’ sales averages are an average based on a survey of research analysts that that provide coverage for Merus.

Merus (NASDAQ:MRUS) last announced its quarterly earnings results on Thursday, May 30th. The biotechnology company reported ($0.30) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.52) by $0.22. The firm had revenue of $8.75 million during the quarter, compared to analyst estimates of $7.47 million. Merus had a negative return on equity of 39.46% and a negative net margin of 75.71%.

A number of analysts recently issued reports on the company. Zacks Investment Research lowered Merus from a “buy” rating to a “hold” rating in a report on Wednesday, March 27th. BidaskClub lowered Merus from a “hold” rating to a “sell” rating in a report on Thursday, May 9th. Citigroup lowered their price target on Merus from $18.00 to $16.00 and set a “neutral” rating for the company in a report on Friday, March 15th. Wedbush lowered their price target on Merus from $34.00 to $25.00 and set an “outperform” rating for the company in a report on Friday, April 5th. Finally, ValuEngine upgraded Merus from a “sell” rating to a “hold” rating in a report on Wednesday, March 6th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and four have issued a buy rating to the stock. The company currently has an average rating of “Hold” and an average target price of $23.00.

Shares of NASDAQ MRUS opened at $13.89 on Wednesday. The stock has a market capitalization of $324.43 million, a price-to-earnings ratio of -7.55 and a beta of 0.21. The company has a 50 day moving average price of $13.71. Merus has a 52-week low of $11.00 and a 52-week high of $26.74.

Institutional investors have recently bought and sold shares of the business. Artal Group S.A. purchased a new stake in Merus during the fourth quarter worth $2,886,000. Morgan Stanley lifted its holdings in Merus by 74.3% during the third quarter. Morgan Stanley now owns 71,643 shares of the biotechnology company’s stock worth $1,415,000 after buying an additional 30,538 shares during the period. Squarepoint Ops LLC lifted its holdings in Merus by 10.3% during the fourth quarter. Squarepoint Ops LLC now owns 11,800 shares of the biotechnology company’s stock worth $165,000 after buying an additional 1,100 shares during the period. Geode Capital Management LLC lifted its holdings in Merus by 18.8% during the fourth quarter. Geode Capital Management LLC now owns 14,987 shares of the biotechnology company’s stock worth $209,000 after buying an additional 2,373 shares during the period. Finally, Granite Investment Partners LLC purchased a new stake in Merus during the first quarter worth $468,000. Institutional investors own 52.13% of the company’s stock.

Merus Company Profile

Merus N.V., a clinical-stage immuno-oncology company, engages in developing bispecific antibody therapeutics. Its bispecific antibody candidate pipeline includes MCLA-128, which is in a Phase II clinical trial for the treatment of patients with metastatic breast cancer; and Phase I/II study for treating gastric, ovarian, endometrial, and non-small cell lung cancers.

Recommended Story: How to find the components of the quick ratio

Get a free copy of the Zacks research report on Merus (MRUS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Merus (NASDAQ:MRUS)

Receive News & Ratings for Merus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merus and related companies with MarketBeat.com's FREE daily email newsletter.